Patrys CEO stepping down after four years
Patrys (ASX:PAB) CEO Dr Marie Roskrow has revealed plans to leave the company at the end of the year.
Roskrow is stepping down as CEO and managing director after a four-year tenure.
The board will search for a replacement through the remainder of the year and has revealed plans to announce the outcome of the search once it is completed.
Roskrow first joined Patrys in 2010 as chief medical officer and president, and was appointed CEO later that year.
“It is with regret that we have today accepted Marie’s resignation,” Patrys Chairman John Read said. “Under Marie’s stewardship the company has made significant progress in meeting its clinical objectives and advancing its novel platform of natural human antibodies for the treatment of cancer.”
Patrys has been conducting clinical trials of its PAT-SM6 antibody candidate in relapsed and refractory multiple myeloma.
Patrys (ASX:PAB) shares were trading 4.76% lower at $0.02 as of around 1 pm on Wednesday.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
